Drug Type Autologous CAR-T |
Synonyms SNC 109, SNC109 |
Target |
Action antagonists, inhibitors |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), IL-13Rα2 inhibitors(Interleukin-13 receptor subunit alpha-2 inhibitors), Immunologic cytotoxicity |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma Multiforme | Phase 1 | China | 26 Dec 2023 | |
| Recurrent Glioblastoma | Phase 1 | China | 24 Jun 2022 |





